Flag of the European Union EU Clinical Trials Register Help

Clinical trials for coated tablet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,757 result(s) found for: coated tablet. Displaying page 240 of 338.
    «« First « Previous 236  237  238  239  240  241  242  243  244  Next» Last»»
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018863-40 Sponsor Protocol Number: BAY63-2521/15096 Start Date*: 2010-07-16
    Sponsor Name:Bayer HealthCare AG
    Full Title: An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretre...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000305-76 Sponsor Protocol Number: CMEK162X2111 Start Date*: 2012-09-03
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors
    Medical condition: colorectal adenocarcinoma. metastatic pancreatic adenocarcinoma melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) FR (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000383-10 Sponsor Protocol Number: 1275.1 Start Date*: 2011-07-06
    Sponsor Name:Boehringer Ingelheim RCV GmBH & Co KG
    Full Title: A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) ES (Completed) HU (Completed) SE (Completed) DK (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001985-86 Sponsor Protocol Number: JX594-HEP024 Start Date*: 2016-09-29
    Sponsor Name:SillaJen Inc.
    Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019968-37 Sponsor Protocol Number: 1245.49 Start Date*: 2011-02-09
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with typ...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) ES (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000776-42 Sponsor Protocol Number: FLO-01 Start Date*: 2012-09-17
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study versus Allopurinol
    Medical condition: Tumor Lysis Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045170 Tumour lysis syndrome PT
    14.1 10027433 - Metabolism and nutrition disorders 10045152 Tumor lysis syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021994-35 Sponsor Protocol Number: A4001098 Start Date*: 2011-06-30
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022818-19 Sponsor Protocol Number: 223AS302 Start Date*: 2011-03-22
    Sponsor Name:Biogen Idec Limited
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.
    Medical condition: amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) SE (Completed) IE (Completed) ES (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016179-31 Sponsor Protocol Number: 1245.36 Start Date*: 2010-10-18
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic the...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) ES (Completed) GB (Completed) FR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003704-35 Sponsor Protocol Number: GS-US-174-0115 Start Date*: 2008-12-11
    Sponsor Name:Gilead Science Incorporated
    Full Title: A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection
    Medical condition: Chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Completed) BG (Completed) DE (Completed) GR (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000491-14 Sponsor Protocol Number: AB12008 Start Date*: 2014-10-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alo...
    Medical condition: Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033158 Ovarian epithelial cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) SK (Prohibited by CA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019283-36 Sponsor Protocol Number: AC-058A201 Start Date*: 2010-08-05
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, admini...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BE (Completed) IT (Completed) AT (Completed) DK (Completed) GB (Completed) ES (Prematurely Ended) SE (Completed) BG (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000714-11 Sponsor Protocol Number: IM101-291 Start Date*: 2013-04-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticostero...
    Medical condition: Active Class III or IV lupus glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) ES (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004411-31 Sponsor Protocol Number: AC-055-308 Start Date*: 2013-02-01
    Sponsor Name:ACTELION PHARMACEUTICALS LTD.
    Full Title: Long term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome.
    Medical condition: Eisenmenger Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10058554 Eisenmenger's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BG (Completed) GB (Completed) DE (Completed) AT (Completed) PT (Completed) ES (Completed) HU (Completed) CZ (Completed) RO (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002102-19 Sponsor Protocol Number: VEG108844 Start Date*: 2008-11-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma
    Medical condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004544-18 Sponsor Protocol Number: CL2-95005-002 Start Date*: 2016-03-23
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal ...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000507-86 Sponsor Protocol Number: 201410 Start Date*: 2017-03-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 52-week open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoiet...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015719-42 Sponsor Protocol Number: M0001-C302 Start Date*: 2010-08-12
    Sponsor Name:Shire-Movetis NV
    Full Title: A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation
    Medical condition: Chronic constipation
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10063582 Constipation chronic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GB (Completed) FR (Completed) NL (Completed) BG (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000123-41 Sponsor Protocol Number: B3D-EW-GHDW Start Date*: 2012-09-20
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
    Medical condition: Postmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10031288 Osteoporosis with fracture LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 236  237  238  239  240  241  242  243  244  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 05:06:21 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA